Photo by nci from unsplash
Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic relationship for unbound TFPI and thrombin generation was confirmed. No serious adverse events and no anti‐drug antibodies… Click to show full abstract
Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic relationship for unbound TFPI and thrombin generation was confirmed. No serious adverse events and no anti‐drug antibodies were observed. explorer™3 data support further clinical development of concizumab in people with hemophilia.
Keywords:
trial safety;
concizumab people;
randomized trial;
safety pharmacokinetics;
people hemophilia
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!